- Home
- Publications
- Publication Search
- Publication Details
Title
Two decades of targeted therapies in acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 35, Issue 3, Pages 651-660
Publisher
Springer Science and Business Media LLC
Online
2021-02-17
DOI
10.1038/s41375-021-01164-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
- (2020) Olivier J. Wouters et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
- (2020) Edward Abadir et al. Journal of Clinical Medicine
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis
- (2020) Audrey Tran et al. BMJ Open
- Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia
- (2020) Audrey A. Tran et al. LEUKEMIA RESEARCH
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
- (2019) Naveen Pemmaraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent drug approvals for acute myeloid leukemia
- (2019) Catherine Lai et al. Journal of Hematology & Oncology
- Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML)
- (2019) Amer M. Zeidan et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
- (2019) Vinay Prasad et al. LANCET ONCOLOGY
- Interpretation of clinical endpoints in trials of acute myeloid leukemia
- (2018) Bruno C. Medeiros LEUKEMIA RESEARCH
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
- (2018) Eytan Stein et al. PHARMACOECONOMICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia
- (2017) Habsah Aziz et al. Frontiers in Pharmacology
- Key cost drivers of pharmaceutical clinical trials in the United States
- (2016) Aylin Sertkaya et al. Clinical Trials
- Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI
- (2016) M. Othus et al. HAEMATOLOGICA
- Precision oncology: origins, optimism, and potential
- (2016) Vinay Prasad et al. LANCET ONCOLOGY
- Precision medicine in acute myeloid leukemia: Hope, hype or both?
- (2016) Vinay Prasad et al. LEUKEMIA RESEARCH
- Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI
- (2016) M. Othus et al. HAEMATOLOGICA
- Secondary mutations as mediators of resistance to targeted therapy in leukemia
- (2015) N. Daver et al. BLOOD
- Failures in Phase III: Causes and Consequences
- (2015) B. Seruga et al. CLINICAL CANCER RESEARCH
- The Strength of Association Between Surrogate End Points and Survival in Oncology
- (2015) Vinay Prasad et al. JAMA Internal Medicine
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease
- (2013) W. Zeijlemaker et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- New sources of drugs for hematologic malignancies
- (2011) M. A. Sukhai et al. BLOOD
- Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm
- (2010) R. B. Walter et al. BLOOD
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
- (2010) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now